COMMUNIQUÉS West-GlobeNewswire
-
Major Shareholder Announcement
02/10/2026 -
LAST CALL - Biocodex Microbiota Foundation invites Canadian academics and scientists to apply for €35,000 ($55,000 CAD based on current exchange rate) research grant to advance microbiota research in human health & disease.
02/10/2026 -
LifeWorks Wellness Center Opens New Facility, Centralizing Care on Main Campus in Clearwater
02/10/2026 -
Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group
02/10/2026 -
iTonic Holdings Ltd Announces 16-for-1 Share Consolidation Effective October 6, 2026
02/10/2026 -
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
02/10/2026 -
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
02/10/2026 -
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
02/10/2026 -
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
02/10/2026 -
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
02/10/2026 -
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
02/10/2026 -
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
02/10/2026 -
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
02/10/2026 -
SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
02/10/2026 -
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
02/10/2026 -
Completion of share buyback programme
02/10/2026 -
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
02/10/2026 -
Standard Dental Labs Acquires Dr. Tooth Dental Lab
02/10/2026 -
European Medicines Agency Validates Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Review
02/10/2026
Pages